XCancer

A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours

Description:

The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in patients with irresectable or metastatic CD44v6-expressing solid malignancies for whom no reasonable systemic treatment options are be available.

Sponsor:

Karolinska University Hospital

Phase:

Early Phase 1

Government Study Link:

NCT06639191 - Click here to see study on

ClinicalTrials.gov

[177Lu]Lu-AKIR001

Isotope(s):
Target(s):
  • CD44v6